Beñat Ariceta
A5103073786- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Signaling Pathways in Disease
- Protein Tyrosine Phosphatases
- Sarcoma Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Cell death mechanisms and regulation
- Chronic Myeloid Leukemia Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Ubiquitin and proteasome pathways
- Chemokine receptors and signaling
- Monoclonal and Polyclonal Antibodies Research
Clinica Universidad de Navarra
2022-2024
Centro de Investigación Biomédica en Red de Cáncer
2019-2024
Navarre Institute of Health Research
2020-2024
Memorial Sloan Kettering Cancer Center
2023
Universidad de Navarra
2019-2022
Centro de Investigación del Cáncer
2019
Instituto de Investigación Biomédica de Salamanca
2019
Universidad de Salamanca
2019
Institute of Molecular Medicine
2019
The diagnosis of myeloid neoplasms (MN) has significantly evolved through the last few decades. Next Generation Sequencing (NGS) is gradually becoming an essential tool to help clinicians with disease management. To this end, most specialized genetic laboratories have implemented NGS panels targeting a number different genes relevant MN. aim present study evaluate performance four targeted gene based on their technical features and clinical utility. A total 32 patient bone marrow samples...
Abstract While myelodysplastic syndromes with del(5q) (del(5q) MDS) comprises a well-defined hematological subgroup, the molecular basis underlying its origin remains unknown. Using single cell RNA-seq (scRNA-seq) on CD34 + progenitors from MDS patients, we have identified cells harboring deletion, characterizing transcriptional impact of this genetic insult disease pathogenesis and treatment response. Interestingly, both non-del(5q) present similar lesions, indicating that all cells, not...
Smoldering multiple myeloma (SMM) precedes (MM). The risk of progression SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors defined for untreated SMM. However, the usefulness such markers in context trials evaluating upfront treatment high-risk (HR SMM) has explored yet, precluding identification baseline alterations leading to drug resistance. For this reason, we carried...
Background: Sanger sequencing remains the gold standard for characterizing genetic variants in short DNA fragments (<700 bp). However, increasing demand TATs and high sensitivities variant detection, particularly oncohematology, is driving need more efficient methods. Next-generation (NGS) has improved sensitivity allows simultaneous analysis of multiple genes, but it still costly time-consuming. Consequently, continues to be widely used. In this study, we have compared with Oxford...
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure relapse is not always helpful; therefore, improved systems to detect early are needed. We hypothesized that the use next generation sequencing (NGS) could be suitable approach for personalized follow-up post-HSCT. To validate our hypothesis, we analyzed by NGS, retrospective set peripheral...
Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient acute myeloid leukemia (AML) that was chemoresistant anthracycline and cytarabine acutely sensitive 5'-azacitidine (5'-Aza) hypomethylating monotherapy, resulting long-term morphological remission. Given the role...
Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with five-year overall survival rate below 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML patients into different prognostic groups. However, this is not validated for treated non-intensive approach, its performance may be suboptimal context. Indeed, transcriptomic landscape of has been less explored it might help group patients. In study,...
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized the mutational status of bone marrow dysplastic cells leukemic blasts, analyzed at onset AML using integrated multidimensional flow cytometry (MFC) immunophenotyping fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct...
Not available.
ABSTRACT While del(5q) MDS patients comprise a well-defined hematological subgroup, the molecular basis underlying its origin, and reason behind relapse after lenalidomide remains unknown. Using scRNA-seq on CD34 + progenitor cells from with we were able to identify harboring deletion, enabling us deeply characterize transcriptional impact of this genetic insult disease pathogenesis treatment response. We found, across all patients, an enrichment in GMP megakaryocyte-erythroid progenitors...